Investors

Product Pipeline

This data is provided as a convenience and for informational purposes only for our shareholders and investors. It is not intended to provide medical advice to consumers or health care professionals. This data was current as of November, 2005. Lilly assumes no duty to update this data for changes since that date.

Lilly Newsroom to search press releases for Lilly Products
More Information for Institutional Investors and Analysts

Timing of submissions and approvals are in the US except where otherwise noted.

Recent Approvals	Timing of Approval

Xigris severe sepsis	Nov - 01

Forteo osteoporosis	Nov - 02

Strattera child and adult ADHD	Nov - 02

Cialis (EU approval) (US approval) erectile dysfunction	Nov - 02 Nov - 03

Symbyax bipolar depression	Dec - 03
Alimta malignant pleural mesothelioma	Feb - 04
second line NSCLC	Aug - 04
Cymbalta major depression	Aug - 04
diabetic peripheral neuropathic pain	Sept - 04

Yentreve (EU approval) stress urinary incontinence	Aug - 04
Byetta type 2 diabetes	Apr - 05

Under Regulatory Review	Timing of Submission

Arxxant (ruboxistaurin) diabetic retinopathy	February 2006

Anticipated Submissions Pending Successful Phase 3 Outcomes	Timing of Submission

prasugrel acute coronary syndrome	2 H 2007
enzastaurin non-hodgkin's lymphoma	late 2010 / early 2011
arzoxifene osteoporosis & prevention of breast cancer	2009
inhaled insulin	2009